Anita Chong

List of Publications by Year
in descending order

205 papers	8,626 citations	38742 50 h-index	54911 84 g-index
207 all docs	207 docs citations	207 times ranked	8969 citing authors

#	Article	IF	Citations
1	Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. Journal of Experimental Medicine, 2005, 201, 779-791.	8.5	395
2	Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4. Immunity, 2013, 38, 918-929.	14.3	356
3	Gut Microbiota Elicits a Protective Immune Response against Malaria Transmission. Cell, 2014, 159, 1277-1289.	28.9	279
4	Modulating Adaptive Immune Responses to Peptide Self-Assemblies. ACS Nano, 2012, 6, 1557-1564.	14.6	243
5	Gradated assembly of multiple proteins into supramolecular nanomaterials. Nature Materials, 2014, 13, 829-836.	27.5	228
6	IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Research, 1998, 58, 2832-7.	0.9	213
7	Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide. Journal of Biological Chemistry, 1995, 270, 12398-12403.	3.4	191
8	PROTECTIVE EFFECT OF ISCHEMIC PRECONDITIONING ON LIVER PRESERVATION-REPERFUSION INJURY IN RATS. Transplantation, 1998, 66, 152-157.	1.0	180
9	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	1.0	172
10	Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. Biomaterials, 2012, 33, 6476-6484.	11.4	160
11	REGULATION OF B CELL FUNCTION BY THE IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE1. Transplantation, 1996, 61, 635-642.	1.0	156
12	The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials, 2013, 34, 8776-8785.	11.4	150
13	Differential immune responses to Î±-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. Journal of Clinical Investigation, 2000, 105, 301-310.	8.2	147
14	Inhibition of Cytomegalovirus in vitro and in vivo by the Experimental Immunosuppressive Agent Leflunomide. Intervirology, 1999, 42, 412-418.	2.8	134
15	Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Biochemical Pharmacology, 1996, 52, 527-534.	4.4	131
16	The impact of infection and tissue damage in solid-organ transplantation. Nature Reviews Immunology, 2012, 12, 459-471.	22.7	128
17	EXPERIENCES WITH LEFLUNOMIDE IN SOLID ORGAN TRANSPLANTATION. Transplantation, 2002, 73, 358-366.	1.0	128
18	NOVEL MECHANISM OF INHIBITION OF CYTOMEGALOVIRUS BY THE EXPERIMENTAL IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE1,2. Transplantation, 1999, 68, 814-825.	1.0	126

#	Article	IF	Citations
19	Reversal of Diabetes in Non-Obese Diabetic Mice Without Spleen Cell-Derived Â Cell Regeneration. Science, 2006, 311, 1774-1775.	12.6	120
20	Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. Journal of Immunology, 1998, 160, 1581-8.	0.8	118
21	The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. Journal of Immunology, 1997, 159, 22-7.	0.8	115
22	Titrating Tâ€Cell Epitopes within Selfâ€Assembled Vaccines Optimizes CD4+ Helper T Cell and Antibody Outputs. Advanced Healthcare Materials, 2014, 3, 1898-1908.	7.6	113
23	The IRF4 Gene Regulatory Module Functions as a Read-Write Integrator to Dynamically Coordinate TÂHelper Cell Fate. Immunity, 2017, 47, 481-497.e7.	14.3	104
24	TLR Signals Promote IL-6/IL-17-Dependent Transplant Rejection. Journal of Immunology, 2009, 182, 6217-6225.	0.8	101
25	Protective Immunity against Recurrent Staphylococcus aureus Skin Infection Requires Antibody and Interleukin-17A. Infection and Immunity, 2014, 82, 2125-2134.	2.2	100
26	IN VIVO ACTIVITY OF LEFLUNOMIDE. Transplantation, 1999, 68, 100-109.	1.0	94
27	A Selfâ€Adjuvanting Supramolecular Vaccine Carrying a Folded Protein Antigen. Advanced Healthcare Materials, 2013, 2, 1114-1119.	7.6	92
28	Multidrug resistance activity in human lymphocytes. Human Immunology, 1991, 32, 134-140.	2.4	90
29	INHIBITION OF HERPES SIMPLEX VIRUS TYPE 1 BY THE EXPERIMENTAL IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE1. Transplantation, 2001, 71, 170-174.	1.0	89
30	LEFLUNOMIDE, A NOVEL IMMUNOSUPPRESSIVE AGENT. Transplantation, 1993, 55, 1361-1366.	1.0	88
31	Liver Ischemia Contributes to Early Islet Failure Following Intraportal Transplantation: Benefits of Liver Ischemic-Preconditioning. American Journal of Transplantation, 2006, 6, 60-68.	4.7	88
32	Concurrent Antiviral and Immunosuppressive Activities of Leflunomide In Vivo. American Journal of Transplantation, 2006, 6, 69-75.	4.7	87
33	The composition of the microbiota modulates allograft rejection. Journal of Clinical Investigation, 2016, 126, 2736-2744.	8.2	86
34	Recovery of Islet Â-Cell Function in Streptozotocin- Induced Diabetic Mice: An Indirect Role for the Spleen. Diabetes, 2006, 55, 3256-3263.	0.6	83
35	Prevention of Allograft Tolerance by Bacterial Infection with <i>Listeria monocytogenes</i>. Journal of Immunology, 2008, 180, 5991-5999.	0.8	83
36	Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses. Journal of Controlled Release, 2018, 282, 120-130.	9.9	77

#	Article	IF	Citations
37	In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide. Biochemical Pharmacology, 1999, 58, 1405-1413.	4.4	76
38	Infection with the Intracellular Bacterium, Listeria monocytogenes, Overrides Established Tolerance in a Mouse Cardiac Allograft Model. American Journal of Transplantation, 2010, 10, 1524-1533.	4.7	74
39	Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. American Journal of Transplantation, 2020, 20, 2652-2668.	4.7	70
40	EFFECTS OF LEFLUNOMIDE AND OTHER IMMUNOSUPPRESSIVE AGENTS ON T CELL PROLIFERATION IN VITRO1. Transplantation, 1996, 61, 140-145.	1.0	67
41	The Multiple Facets of Toll-Like Receptors in Transplantation Biology. Transplantation, 2008, 86, 1-9.	1.0	66
42	Reversing Endogenous Alloreactive B Cell GC Responses With Anti-CD154 or CTLA-4Ig. American Journal of Transplantation, 2013, 13, 2280-2292.	4.7	66
43	Cutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients. Journal of Immunology, 2015, 195, 4069-4073.	0.8	66
44	In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. Journal of Immunology, 1997, 159, 167-74.	0.8	64
45	IL-6 Induced by Staphylococcus aureus Infection Prevents the Induction of Skin Allograft Acceptance in Mice. American Journal of Transplantation, 2011, 11, 936-946.	4.7	63
46	Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. Journal of Immunology, 1989, 142, 2133-9.	0.8	62
47	Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers. Biomaterials, 2017, 149, 1-11.	11.4	61
48	Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunology, Immunotherapy, 1993, 36, 133-139.	4.2	59
49	PHARMACOLOGICALLY INDUCED REGRESSION OF CHRONIC TRANSPLANT REJECTION. Transplantation, 1995, 60, 1065-1072.	1.0	56
50	Cutting Edge: NK Cells Mediate IgG1-Dependent Hyperacute Rejection of Xenografts. Journal of Immunology, 2004, 172, 7235-7238.	0.8	56
51	CD54/ICAM-1 Is a Costimulator of NK Cell-Mediated Cytotoxicity. Cellular Immunology, 1994, 157, 92-105.	3.0	46
52	DELAYED XENOGRAFT REJECTION IN THE CONCORDANT HAMSTER HEART INTO LEWIS RAT MODEL1. Transplantation, 1996, 62, 90-96.	1.0	46
53	Spontaneous restoration of transplantation tolerance after acute rejection. Nature Communications, 2015, 6, 7566.	12.8	45
54	Delayed Cytotoxic T Lymphocyteâ€"Associated Protein 4â€"Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection. American Journal of Transplantation, 2016, 16, 2312-2323.	4.7	45

#	Article	IF	Citations
55	Memory Alloreactive B Cells and Alloantibodies Prevent Anti-CD154-Mediated Allograft Acceptance. Journal of Immunology, 2009, 182, 1314-1324.	0.8	44
56	Lessons and Limits of Mouse Models. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015495-a015495.	6.2	44
57	Memory B Cells in Transplantation. Transplantation, 2015, 99, 21-28.	1.0	44
58	Transcriptional Regulation of Fas Gene Expression by GA-binding Protein and AP-1 in T Cell Antigen ReceptorÂ·CD3 Complex-stimulated T Cells. Journal of Biological Chemistry, 1999, 274, 35203-35210.	3.4	41
59	Alloantibodies Prevent the Induction of Transplantation Tolerance by Enhancing Alloreactive T Cell Priming. Journal of Immunology, 2011, 186, 214-221.	0.8	41
60	Glycemic Control Promotes Pancreatic Beta-Cell Regeneration in Streptozotocin-Induced Diabetic Mice. PLoS ONE, 2010, 5, e8749.	2.5	41
61	Toll-like receptor signaling in transplantation. Current Opinion in Organ Transplantation, 2008, 13, 358-365.	1.6	40
62	Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection. American Journal of Transplantation, 2019, 19, 2155-2163.	4.7	39
63	Expression of Complement Regulatory Proteins in Accommodated Xenografts Induced by Anti-Î±-Gal IgG1 in a Rat-to-Mouse Model. American Journal of Transplantation, 2008, 8, 32-40.	4.7	36
64	Mechanisms and Consequences of Injury and Repair in Older Organ Transplants. Transplantation, 2014, 97, 1091-1099.	1.0	35
65	Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. American Journal of Transplantation, 2020, 20, 2675-2685.	4.7	35
66	Impact of Immunosuppression on Recall Immune Responses to Influenza Vaccination in Stable Renal Transplant Recipients. Transplantation, 2014, 97, 846-853.	1.0	34
67	Mechanisms of organ transplant injury mediated by B cells and antibodies: Implications for antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 23-32.	4.7	34
68	Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejection. Nature Communications, 2021, 12, 4372.	12.8	34
69	Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T _H 17 responses. Science Advances, 2020, 6, eaba0995.	10.3	33
70	Peripheral deletion of mature alloreactive B cells induced by costimulation blockade. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12093-12098.	7.1	32
71	Erosion of Transplantation Tolerance After Infection. American Journal of Transplantation, 2017, 17, 81-90.	4.7	32
72	Enabling sublingual peptide immunization with molecular self-assemblies. Biomaterials, 2020, 241, 119903.	11.4	32

#	Article	IF	Citations
73	Local Inflammation Exacerbates the Severity of Staphylococcus aureus Skin Infection. PLoS ONE, 2013, 8, e69508.	2.5	32
74	Mechanistic Study of Malononitrileamide FK778 in Cardiac Transplantation and CMV Infection in Rats. Transplantation, 2005, 79, 17-22.	1.0	31
75	Self-Antigen-Driven Thymic B Cell Class Switching Promotes T Cell Central Tolerance. Cell Reports, 2016, 17, 387-398.	6.4	31
76	High-Fat Dietâ€"Induced Obesity Enhances Allograft Rejection. Transplantation, 2016, 100, 1015-1021.	1.0	30
77	Stimulation of IFN-Î³, TNF-Î±, and TNF-Î² secretion in IL-2-activated T cells: Costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules. Cellular Immunology, 1992, 144, 69-79.	3.0	29
78	Hyperacute Rejection by Anti-Gal IgG1, IgG2a, and IgG2b Is Dependent on Complement and Fc-Î³ Receptors. Journal of Immunology, 2008, 180, 261-268.	0.8	28
79	The influence of the microbiota on the immune response to transplantation. Current Opinion in Organ Transplantation, 2015, 20, 1-7.	1.6	28
80	Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. American Journal of Transplantation, 2020, 20, 3620-3630.	4.7	27
81	B cells as antigen-presenting cells in transplantation rejection and tolerance. Cellular Immunology, 2020, 349, 104061.	3.0	27
82	Nonimmune lymphocyte-macrophage interaction. Cellular Immunology, 1985, 92, 277-289.	3.0	26
83	Transplantation tolerance and its outcome during infections and inflammation. Immunological Reviews, 2014, 258, 80-101.	6.0	26
84	Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. Journal of Neuroimmunology, 2014, 272, 67-75.	2.3	26
85	Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation. Transplantation, 2016, 100, 1683-1691.	1.0	26
86	THE PORTOSYSTEMIC SHUNT PROTECTS LIVER AGAINST ISCHEMIC REPERFUSION INJURY1. Transplantation, 1999, 68, 958-963.	1.0	26
87	Mouse-heart grafts expressing an incompatible carbohydrate antigen. II. Transition from accommodation to tolerance. Transplantation, 2004, 77, 366-373.	1.0	25
88	Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Frontiers in Immunology, 2017, 8, 641.	4.8	25
89	HISTOLOGICAL CHARACTERIZATION AND PHARMACOLOGICAL CONTROL OF CHRONIC REJECTION IN XENOGENEIC AND ALLOGENEIC HEART TRANSPLANTATION1. Transplantation, 1998, 66, 692-698.	1.0	25
90	THE STRUCTURE OF ANTI-GAL IMMUNOGLOBULIN GENES IN NA??VE AND STIMULATED GAL KNOCKOUT MICE. Transplantation, 2001, 72, 1817-1825.	1.0	24

#	Article	IF	Citations
91	MODIFICATION OF HUMORAL RESPONSES BY THE COMBINATION OF LEFLUNOMIDE AND CYCLOSPORINE IN LEWIS RATS TRANSPLANTED WITH HAMSTER HEARTS1,2. Transplantation, 1997, 64, 1650-1657.	1.0	24
92	Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression. Transplantation Proceedings, 1993, 25, 747-9.	0.6	24
93	In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium. Journal of Immunology, 1998, 160, 846-53.	0.8	24
94	Allograft tolerance induced by intact active bone co-transplantation and anti-CD40L monoclonal antibody therapy1. Transplantation, 2002, 74, 345-354.	1.0	23
95	Induction of species-specific host accommodation in the hamster-to-rat xenotransplantation model. Journal of Immunology, 1998, 161, 2044-51.	0.8	23
96	Cellular Therapies for Type 1 Diabetes. Hormone and Metabolic Research, 2008, 40, 147-154.	1.5	22
97	Matchmaking the B-Cell Signature of Tolerance to Regulatory B Cells. American Journal of Transplantation, 2011, 11, 2555-2560.	4.7	22
98	Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice. Frontiers in Immunology, 2017, 8, 1169.	4.8	22
99	Pregnancy-induced humoral sensitization overrides T cell tolerance to fetus-matched allografts in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	22
100	Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Cancer Immunology, Immunotherapy, 1989, 29, 270-8.	4.2	21
101	Transplantation tolerance: don't forget about the B cells. Clinical and Experimental Immunology, 2017, 189, 171-180.	2.6	21
102	Skin-restricted commensal colonization accelerates skin graft rejection. JCI Insight, 2019, 4, .	5.0	21
103	PROLONGATION OF RAT ISLET ALLOGRAFT SURVIVAL BY THE IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE. Transplantation, 1997, 63, 711-716.	1.0	21
104	Non-depleting anti-CD4, but not anti-CD8, antibody induces long-term survival of xenogeneic and allogeneic hearts in Î±1,3-galactosyltransferase knockoutâ€¨(GT-Ko) mice. Xenotransplantation, 2000, 7, 275-283.	2.8	20
105	Impact of <i>Staphylococcus aureus</i> USA300 Colonization and Skin Infections on Systemic Immune Responses in Humans. Journal of Immunology, 2016, 197, 1118-1126.	0.8	20
106	Tracking of TCR-Transgenic T Cells Reveals That Multiple Mechanisms Maintain Cardiac Transplant Tolerance in Mice. American Journal of Transplantation, 2016, 16, 2854-2864.	4.7	19
107	Direct killing of xenograft cells by CD8+ T cells of discordant xenograft recipients1. Transplantation, 2002, 74, 1587-1595.	1.0	18
108	Long-Term Control of Alloreactive B Cell Responses by the Suppression of T Cell Help. Journal of Immunology, 2008, 180, 6077-6084.	0.8	18

#	Article	IF	Citations
109	Heterogeneity of memory B cells. American Journal of Transplantation, 2018, 18, 779-784.	4.7	18
110	IMMUNOSUPPRESSION PREVENTING CONCORDANT XENOGENEIC ISLET GRAFT REJECTION IS NOT SUFFICIENT TO PREVENT RECURRENCE OF AUTOIMMUNE DIABETES IN NONOBESE DIABETIC MICE. Transplantation, 1998, 65, 1310-1314.	1.0	18
111	FK506 TREATMENT IN COMBINATION WITH LEFLUNOMIDE IN HAMSTER-TO-RAT HEART AND LIVER XENOGRAFT TRANSPLANTATION. Transplantation, 1998, 66, 832-837.	1.0	18
112	Bioluminescence Imaging Visualizes Activation of Nuclear Factor-Î ºB in Mouse Cardiac Transplantation. Transplantation, 2008, 85, 903-910.	1.0	17
113	Antagonistic Effect of Toll-Like Receptor Signaling and Bacterial Infections on Transplantation Tolerance. Transplantation, 2009, 87, S77-S79.	1.0	17
114	Microbes and Allogeneic Transplantation. Transplantation, 2014, 97, 5-11.	1.0	17
115	Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance. Cell Reports, 2018, 24, 2112-2126.	6.4	17
116	GRANULOCYTE COLONY-STIMULATING FACTOR IMMUNOMODULATION IN THE RAT CARDIAC TRANSPLANTATION MODEL. Transplantation, 1996, 61, 1122-1125.	1.0	17
117	Nonimmune lymphocyte-macrophage interaction. Cellular Immunology, 1985, 92, 265-276.	3.0	16
118	Cell surface receptors for sulphated polysaccharides: a potential marker for macrophage subsets. Immunology, 1986, 58, 277-84.	4.4	16
119	IFN-Î³ Production Is Specifically Regulated by IL-10 in Mice Made Tolerant with Anti-CD40 Ligand Antibody and Intact Active Bone. Journal of Immunology, 2003, 170, 853-860.	0.8	15
120	Role of bacterial infections in allograft rejection. Expert Review of Clinical Immunology, 2008, 4, 281-293.	3.0	15
121	Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin. PLoS ONE, 2013, 8, e65777.	2.5	15
122	Transplantation tolerance modifies donor-specific B cell fate to suppress de novo alloreactive B cells. Journal of Clinical Investigation, 2020, 130, 3453-3466.	8.2	15
123	Equal Expansion of Endogenous Transplant-Specific Regulatory T Cell and Recruitment Into the Allograft During Rejection and Tolerance. Frontiers in Immunology, 2018, 9, 1385.	4.8	14
124	New insights into the development of B cell responses: Implications for solid organ transplantation. Human Immunology, 2019, 80, 378-384.	2.4	14
125	IN VIVO EFFECTS OF LEFLUNOMIDE ON NORMAL PANCREATIC ISLET AND SYNGENEIC ISLET GRAFT FUNCTION. Transplantation, 1997, 63, 716-721.	1.0	14
126	QUANTITATION OF THE CHANGES IN SPLENIC ARCHITECTURE DURING THE REJECTION OF CARDIAC ALLOGRAFTS OR XENOGRAFTS1. Transplantation, 1997, 64, 448-453.	1.0	14

#	Article	IF	Citations
127	CD45-cross-linking stimulates IFN-gamma production in NK cells. Journal of Immunology, 1995, 154, 644-52.	0.8	14
128	Resilience of T cell-intrinsic dysfunction in transplantation tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23682-23690.	7.1	13
129	Inhibition of protective immunity against <i>Staphylococcus aureus</i> infection by MHC-restricted immunodominance is overcome by vaccination. Science Advances, 2020, 6, eaaw7713.	10.3	13
130	Gene gun-mediated gene transfer and expression in rat islets. Transplantation Proceedings, 1997, 29, 2209-2210.	0.6	12
131	Acute Xenograft Rejection Mediated by Antibodies Produced Independently of TH 1/TH 2 Cytokine Profiles. American Journal of Transplantation, 2002, 2, 526-534.	4.7	12
132	CD4+ T Cells Are Sufficient to Elicit Allograft Rejection and Major Histocompatibility Complex Class I Molecule Is Required to Induce Recurrent Autoimmune Diabetes After Pancreas Transplantation in Mice. Transplantation, 2008, 85, 1205-1211.	1.0	12
133	Tolerance of T-independent xeno-antibody responses in the hamster-to-rat xenotransplantation model is species-restricted but not tissue-specific. Xenotransplantation, 2000, 7, 48-57.	2.8	11
134	Role of CD4+ and CD8+ T cells in the rejection of concordant pancreas xenografts1. Transplantation, 2002, 74, 1236-1241.	1.0	11
135	Plasma cell densities and glomerular filtration rates predict renal allograft outcomes following acute rejection. Transplant International, 2012, 25, 1050-1058.	1.6	11
136	Proteomic Identification of <i>saeRS</i> -Dependent Targets Critical for Protective Humoral Immunity against Staphylococcus aureus Skin Infection. Infection and Immunity, 2015, 83, 3712-3721.	2.2	11
137	The pursuit of transplantation tolerance: new mechanistic insights. Cellular and Molecular Immunology, 2019, 16, 324-333.	10.5	11
138	ANTI-CD4 THERAPY IN COMBINED HEART-KIDNEY, HEART-LIVER, AND HEART-SMALL BOWEL ALLOTRANSPLANTS IN HIGH-RESPONDER RATS1. Transplantation, 1998, 66, 1-5.	1.0	11
139	CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients. JCI Insight, 2017, 2, .	5.0	11
140	Thrombomodulin in the treatment of atherothrombotic diseases. Frontiers in Bioscience - Elite, 2009, 1, 33.	1.8	11
141	Molecular phenotyping of T-cell-mediated rejection. Nature Reviews Nephrology, 2014, 10, 678-680.	9.6	10
142	Establishment of a Global Virtual Laboratory for Transplantation. Transplantation, 2015, 99, 381-384.	1.0	10
143	Cross-linking of CD45 on NK cells stimulates p56lck-mediated tyrosine phosphorylation and IFN-gamma production. Journal of Immunology, 1995, 155, 5241-8.	0.8	10
144	Leflunomide immunosuppression in rat small intestinal transplantation. Transplantation Proceedings, 1994, 26, 1599-600.	0.6	10

#	Article	IF	Citations
145	Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation, 1994, 57, 1223-31.	1.0	10
146	Toward an understanding of allogeneic conflict in pregnancy and transplantation. Journal of Experimental Medicine, 2022, 219, .	8.5	10
147	Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants. Cancer Immunology, Immunotherapy, 1989, 30, 65-70.	4.2	9
148	LEWIS RAT PANCREAS, BUT NOT CARDIAC XENOGRAFTS, ARE RESISTANT TO ANTI-GAL ANTIBODY MEDIATED HYPERACUTE REJECTION 1. Transplantation, 2001, 71, 1385-1389.	1.0	9
149	Importance of B Lymphocytes and the IgG-Binding Protein Sbi in Staphylococcus aureus Skin Infection. Pathogens, 2016, 5, 12.	2.8	9
150	Adoptive Transfer of Tracer-Alloreactive CD4+ T Cell Receptor Transgenic T Cells Alters the Endogenous Immune Response to an Allograft. American Journal of Transplantation, 2016, 16, 2842-2853.	4.7	9
151	Evolving Approaches in the Identification of Allograft-Reactive T and B Cells in Mice and Humans. Transplantation, 2017, 101, 2671-2681.	1.0	9
152	Blocking of lymphokine activated killer (LAK) cell mediated cytotoxicity by cell-sized beads bearing tumor cell proteins. Journal of Immunology, 1988, 141, 4418-24.	0.8	9
153	Host-versus-commensal immune responses participate in the rejection of colonized solid organ transplants. Journal of Clinical Investigation, 2022, 132, .	8.2	9
154	Phenotypic analyses of lymphokine-activated killer cells that release interferon Î³ and tumor necrosis factor Î±. Cancer Immunology, Immunotherapy, 1990, 31, 255-259.	4.2	8
155	Evidence that tilapia islets do not express alpha-(1,3)gal: implications for islet xenotransplantation. Xenotransplantation, 2004, 11, 276-283.	2.8	8
156	Experimental models of B cell tolerance in transplantation. Seminars in Immunology, 2012, 24, 77-85.	5.6	8
157	Desensitization in the Era of Precision Medicine: Moving From the Bench to Bedside. Transplantation, 2019, 103, 1574-1581.	1.0	8
158	EFFECT OF ANTI-CD4 MONOCLONAL ANTIBODY COMBINED WITH HUMAN CTLA4Ig ON THE SURVIVAL OF HAMSTER LIVER AND HEART XENOGRAFTS IN LEWIS RATS. Transplantation, 1997, 64, 317-321.	1.0	7
159	Natural killer cell cytotoxicity and the multidrug resistance gene. Transplantation Proceedings, 1993, 25, 96-7.	0.6	7
160	Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action. Journal of Pharmacology and Experimental Therapeutics, 1997, 283, 869-75.	2.5	7
161	Monoclonal antibodies anti-CD3, anti-TCRÎ±Î² and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon Î³. Cancer Immunology, Immunotherapy, 1992, 35, 335-341.	4.2	6
162	Improved Viability of Hepatic Allografts from Fasted Donors Is Associated with Decreased Peripheral TNF Activity. Journal of Surgical Research, 1995, 58, 337-343.	1.6	6

#	Article	IF	Citations
163	Making a B-Line for Transplantation Tolerance. American Journal of Transplantation, 2011, 11, 420-421.	4.7	6
164	Sex matters: COVID-19 in kidney transplantation. Kidney International, 2021, 99, 555-558.	5.2	6
165	Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation, 1994, 58, 828-34.	1.0	6
166	Response to Comment on Chong et al. on Diabetes Reversal in NOD Mice. Science, 2006, 314, 1243b-1243b.	12.6	5
167	Transplantation tolerance after allograft rejection. Current Opinion in Organ Transplantation, 2017, 22, 64-70.	1.6	5
168	Fifty Shades of Transplantation Tolerance: Beyond a Binary Tolerant/Non-Tolerant Paradigm. Current Transplantation Reports, 2017, 4, 262-269.	2.0	5
169	MyD88 in antigen-presenting cells is not required for CD4⁺ T-cell responses during peptide nanofiber vaccination. MedChemComm, 2018, 9, 138-148.	3.4	5
170	Regulation of Alloantibody Responses. Frontiers in Cell and Developmental Biology, 2021, 9, 706171.	3.7	5
171	Inactivation of kupffer cells after prolonged donor fasting improves viability of transplanted hepatic allografts. Hepatology, 1995, 22, 1236-1242.	7.3	5
172	Successful xenotransplantation of adult porcine islets in NOD and BALB/c mice with leflunomide and cyclosporine. Transplantation Proceedings, 1997, 29, 2166-2167.	0.6	4
173	Modification of the clonogenic assay for the detection of lymphokine activated killer cell activity. Journal of Immunological Methods, 1990, 128, 119-126.	1.4	3
174	Leflunomide, a potential immunosuppressant for pancreatic islet transplantation. Transplantation Proceedings, 1997, 29, 1296-1297.	0.6	3
175	Alone Again, Naturally. Transplantation, 2017, 101, 1956-1958.	1.0	3
176	An optimized protocol to quantify signaling in human transitional B cells by phospho flow cytometry. Journal of Immunological Methods, 2018, 463, 112-121.	1.4	3
177	The First ITS Meeting. Transplantation, 2020, 104, 1114-1116.	1.0	3
178	Impaired T-Lymphocyte Responses During Childhood <i>Staphylococcus aureus</i> Infection. Journal of Infectious Diseases, 2022, 225, 177-185.	4.0	3
179	Semiallogeneic Pregnancy: A Paradigm Change for T-cell Transplantation Tolerance. Transplantation, 2022, 106, 1098-1100.	1.0	3
180	Effect of leflunomide and cyclosporine on concordant xenogeneic islet transplantation in streptozotocin-induced and autoimmune diabetic mice. Transplantation Proceedings, 1997, 29, 2155.	0.6	2

#	Article	IF	Citations
181	Seeing is believing: How the MIP-luc mouse can advance the field of islet transplantation and Î²-cell regeneration. Islets, 2010, 2, 261-262.	1.8	2
182	B cells assist allograft rejection in the deficiency of protein kinase c-theta. Transplant International, 2013, 26, 919-927.	1.6	2
183	Incorporation of sex and gender guidelines into transplantation literature. Transplantation, 2021, Publish Ahead of Print, e261-e262.	1.0	2
184	Complete control of humoral and cell-mediated xenoreactions with the combination of leflunomide and cyclosporine. Transplantation Proceedings, 1996, 28, 684.	0.6	2
185	Oral alloantigen exposure promotes donor-specific tolerance in a mouse model of minor-mismatched skin transplantation. American Journal of Transplantation, 2022, 22, 2348-2359.	4.7	2
186	Linked sensitization by memory CD4+ T cells prevents costimulation blockadeâ€“induced transplantation tolerance. JCI Insight, 2022, 7, .	5.0	2
187	Ability of cell-sized beads bearing tumor cell membrane proteins to stimulate LAK cells to secrete interferon-Î³ and tumor necrosis factor-Î±1. Cellular Immunology, 1991, 134, 96-110.	3.0	1
188	INHIBITION OF XENOGENEIC ANTI-ATG ANTIBODY PRODUCTION BY LEFLUNOMIDE IN ATG-TREATED RATS RESULTS IN SUPERIOR GRAFT PROTECTION.. Transplantation, 2000, 69, S191.	1.0	1
189	From Pipe Dream to Donor-Specific PC Elimination. Transplantation, 2016, 100, 2238-2239.	1.0	1
190	Virtual Global Transplant Laboratory Standard Operating Protocol for Donor Alloantigen-specific Interferon-gamma ELISPOT Assay. Transplantation Direct, 2016, 2, e111.	1.6	1
191	B Cell Recruitment Follows Kidney Injury and Maladaptive Repair. Transplantation, 2019, 103, 1527-1529.	1.0	1
192	Differential Effect of Leflunomide on Concordant Xenogeneic Islet Graft Rejection and Recurrence of Autoimmune Diabetes. Transplantation Proceedings, 1998, 30, 463-464.	0.6	0
193	HYPERACUTE REJECTION OF RAT OR MOUSE HEARTS BY Î±l,3 GALACTOSYLTRANSFERASE KNOCK-OUT MICE.. Transplantation, 2000, 69, S253.	1.0	0
194	Quantifying pancreatic beta-cell regeneration. Journal of the American College of Surgeons, 2008, 207, S106-S107.	0.5	0
195	B AND PLASMA CELLS, BUT NOT C4D, IN RENAL BIOPSIES DURING ACUTE REJECTION ARE SENSITIVE MARKERS OF POOR GRAFT OUTCOME. Transplantation, 2010, 90, 367.	1.0	0
196	Three Strikes and Youâ€™re Cured. Science Translational Medicine, 2012, 4, 133fs12.	12.4	0
197	â€œTip-Toeingâ€•to an Assay for Transplantation Tolerance?. American Journal of Transplantation, 2012, 12, 519-520.	4.7	0
198	Literature WatchImplications for transplantation. American Journal of Transplantation, 2013, 13, 1943-1943.	4.7	0

#	Article	IF	Citations
199	New Kid on the Pretransplant Block: IgG Recognizing Apoptotic Cells. American Journal of Transplantation, 2014, 14, 1477-1478.	4.7	0
200	Urinary nanosensors of early transplant rejection. Nature Biomedical Engineering, 2019, 3, 251-252.	22.5	0
201	ITS finally here! The first International Transplant Science meeting jointly organized by AST, ESOT, and TTS. Transplantation, 2019, 103, 1975-1976.	1.0	0
202	Splanchnic transplantation. Transplantation Proceedings, 1994, 26, 1411-2.	0.6	0
203	Allograft ultraviolet-B irradiation in rat small intestinal transplantation. Transplantation Proceedings, 1994, 26, 1624-5.	0.6	0
204	Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation. The Cochrane Library, 2022, 2022, .	2.8	0
205	The Women of FOCIS: Promoting Equality and Inclusiveness in a Professional Federation of Clinical Immunology Societies. Frontiers in Immunology, 2022, 13, 816535.	4.8	0